Литература

Поставить закладку

Избранные главы гериатрической урологии / под общ. ред. Л.М. Гори лов- ского. – М.: Ньюдиамед, 2000. – 374 с.
Мартов А.Г., Корниенко С.И., Гущин Б.Л. и др. Интраоперационные ос- ложнения при трансуретральных оперативных вмешательствах по по- воду доброкачественной гиперплазии предстательной (ТУР) железы // Урология. – 2005. – С. 3–8.
Руководство по урологии: В 3 т. / под общ. ред. Н.А. Лопаткина. – М.: Медицина, 1998. – Т. 3.
Abrams Р.Н., Farrar D.J., TumerWarwick R.T. et al. The results ofprostatec tomy: A symptomatic and urodynamic analysis of 152 patients // J. Urol. – 1979. – Vol. 121. P. 640642.
Ahmed M., Bell T., Lawrence W.T. et al. Transurethral microwavethermo therapy (Prostatron version 2.5) compared with transurethral resection of thepros tate for the treatment of benign prostatic hyperplasia: A randomizedcontrolledpar allel study // Br.J. Urol. 1997. Vol. 79. P. 181185.
Alsikafi N.F., Gerber G.S. Bilateral metachronous testicular seminomaasso ciated with microlithiasis // J. Urol. – 1998. – Vol. 159. – P. 1643–1644.
Barry M J. Prostate specific antigen. Testing for early diagnosis of prostate cancer // N.Eng. J. Med. 2001. Vol. 344. 13731377.
Barry M.J., Fowler F.J. Jr., O’Leary M.P. et al. The American UrologicalAs sociation symptom index for benign prostatic hyperplasia. The MeasurementCom mittee ofthe American Urological Association // J. Urol. – 1992. –Vol. 148. – P. 15491557.

Blanker M. H., Bohnen A. M., Groeneveld F. P. et al. Normal voiding pat temsanddeterminants of increased diurnal and nocturnal voiding frequency in el derlymen // J. Urol. – 2000. – Vol. 164. – P. 1201–1205.
Boyle P. Epidemiology of benign prostatic hyperplasia: risk factors andcon comitance with hypertension // Br.J. Clin. Pract. – 1994. – Vol. 74. – P. 18–22.
Boyle P., Robertson C., Lowe E, Roehbom C. Metaanalysis of clinical trialsof Permixon in the treatment ofbenign prostatic hyperplasia // Urology. – 2000. Vol. 55. P. 533539.
Brawer М.К. Diagnosis of lower urinary tract symptoms // Postgrad. Med. Special. Report. – 1999. – P. 7–10.
Cecil R.L. Cecil Textbook of Medicine. 20th ed. // Philadelphia: WBSaun ders. 1996. 2233 p.
Craigen A., Hickling J., Saunders C., Carpenter R. The natural history of prostatic obstruction: A prospective survey // J.R. Coll. Gen. Pract. – 1969. – Vol.18. P. 226232.
Djavan B., Roehrbom C.G., Shariat S. et al. Prospective randomizedcom parison of high energy transurethral microwave thermotherapy versus alphablocker treatment of patients with benign prostatic hyperplasia // J. Urol. –1999. – Vol. 161. P. 139143.
Flanigan R.C., Reda D.J., Wasson J.H. et al. 5year outcome of surgicalre section and watchful waiting for men with moderately symptomatic benignprostatic hyperplasia: A Department of Veterans Aff airs Cooperative Study // J. Urol. – 1998.Vol. 160.P. 1216.
Francisca E.A., d’Ancona F. C., Meuleman E.J. et al. Sexual function fol lowinghigh energy microwave thermotherapy: results of a randomized controlled studycomparing transurethral microwave thermotherapy to transurethral prostati cresection // J. Urol. 1999. Vol. 161. P. 486490.
Gerber G.S. Benign prostatic hyperplasia in older men // Clin. Geriatr. Med. 1998. Vol. 14. P. 317331.
Girman C.J., Jacobsen S.J., Guess H.A. et al. Natural history of prostatism: relationship among symptoms, prostate volume and peak urinary flow // J. Urol. – 1995. Vol. 153. P. 15101515.
Gormley G.J., Stoner E., Bruskewitz R.C. et al. The effect of finasteridein men with benign prostatic hyperplasia. The Finasteride Study Group // N.Eng. J. Med. 1992. Vol. 327. P. 11851191.
Guess H.A. Epidemiology and natural history offbenign prostatic hyperplasia // Urol. Clin. North. Am. 1995. Vol. 22. P. 247261.
Hoff man R M., MacDonald R, Wilt T.J. Laser prostatectomy forbenignprostatic obstruction (Cochrane Review) // The Cochrane Library. –2004. – Vol. 1. – P. 24.
Isaacs J.T., Coffey D.S. Etiology and disease process of benign prostatic hyperplasia // Prostate. – 1989. – Vol. 2. – P. 33–50.
Jensen K.M.E. Clinical evaluation of routine urodynamic investigationsin prostatism // Neurourol. Urodynam. – 1989. – Vol. 8. – P. 545–578.
Kirby R., Boyle P., Fitzpatrick J. et al. Textbook of Benign ProstaticHyper plasia. – Oxford: Isis Medical Media, 1996. – P. 125–135.
Lepor H., Williford W.O., Barry M.J. et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Aff airs CooperativeStudies Benign Prostatic Hyperplasia Study Group // N.Eng. J. Med. –1996. – Vol. 335. – P. 533539.
Lepor H., Williford W. O., Barry M. J. et al. The impact of medical thera pyonbother due to symptoms, quality of life and global outcome, and factors pre dictingresponse. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia StudyGroup // J. Urol. 1998. Vol. 160. P. 13581367.
Lowe F.C., Fagelman E. Phytotherapy in the treatment of benign prostatic hyperplasia: an update // Urology. – 1999. – Vol. 53. – P. 671–678.
MatthiesenT.B., RittigS., MortensenJ.T., DjurhuusJ.C.Nocturiaandpoly uriain men referred with lower urinary tract symptoms, assessed using a 7dayfre quencyvolume chart // Br.J. Urol. Int. – 1999. – Vol. 83. – P. 1017–1022.
Medina J.J., Parra R.O., Moore R.G. Benign prostatic hyperplasia (theag ingprostate) // Med. Clin. North. Alll. 1999. Vol. 83. P. 12131229.
MeyhoflH.H., Ingemann L., Nordling J., Hald T. Accuracy in preoperati veestimation ofprostatic size. A comparative evaluation of rectal palpation, intra venouspyelography, urethral closure pressure profile recording andcystourethros copy // Scand. J. Urol. Nephrol. – 1981. – Vol. 15. – P. 45–51.
Neal D.E., Ramsden P.D., Sharpies L. et al. Outcome of electiveprostatectomy // BMJ. – 1989. – Vol. 299. – P. 762–767.
Neal D.E., Styles R.A., Powell P.H. et al. Relationship between voiding pressure, symptoms andurodynamicfindingsin253menundergoingprostatectomy // Br.J. Urol. 1987. Vol. 60. P. 554559.
Nyman M.A., Schwenk N.M., Silverstein M.D. Management ofurinaryretention: rapid versus gradual decompression and risk of complications // MayoClin. Proc. 1997. Vol. 72. P. 951956.
Riehmann M., Knes J.M., Heisey D. et al. Transurethral resection versusincision of the prostate: a randomized, prospective study // Urology. – 1995. Vol. 45. P. 768775.
Roehrbom C.G., Preminger G., Newhall P. et al. Microwave thermotherapyfor benign prostatic hyperplasia with the Domier Urowave: Results of a randomizeddoubleblind multicenter shamcontrolled trial // Urology. – 1998.Vol. 51.P. 1928.
Rowan D., James E.D., Kramer AE. et al. Urodynamic equipment: technicalaspects. Produced by the International Continence Society Working Party onUrodynamic Equipment // J.Med. Eng. Technol. – 1987. – Vol. 11. – P. 57–64.
Shingleton W.B., Farabaugh P., May W. Threeyear followup of laserprostatectomy versus transurethral resection of the prostate in men with benignprostatichyperplasia // Urology. – 2002. – Vol. 60. – P. 305–308.
Toscano I.L., Maciel L. C., Martins F.G. et al. Transurethral resection of theprostate: Prospective randomized study of catheter removal after 24 or 48 hours following surgery // Braz.J. Urol. – 2001. – Vol. 27. – P. 144–147.
Van Melick H.H., Van Venrooij G.E., Eckhardt M. D et al. A randomizedcontrolled trial comparing transurethral resection of the prostate, contact laserprostatectomy and electrovaporization in men with benign prostatic hyperplasia: urodynamic effects // J. Urol. – 2002. – Vol. 168. – P. 1058–1062.
Van Venrooij G.E., Eckhardt M.D,, Gisholf K.W., Boon T.A. Data fromfrequencyvolume charts versus symptom scores and quality of life score in menwith lower urinary tract symptoms due to benign prostatic hyperplasia // Eur. Urol. 2001. Vol. 39. P. 4247.
Wagrell L., Schelin S., Nordling J. et al. Feedback microwave thermotherapyversus TURP for clinical BPH: A randomized controlled multicenter study // Urology. 2002. Vol. 60. P. 292299.
WassonJ.,RedaD.,BmskewitzR.C.etal.Acomparisonoftiansurethralsuigery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. The Veterans Affairs Cooperative Study Group on Transurethral Resection of theProstate // N.Eng. J. Med. 1994. Vol. 334. P. 7579.
Wilde M.I., Goa K.L. Finasteride: an update of its use in the management ofsymptomatic benign prostatic hyperplasia // Drugs. – 1999. – 57. – P. 557– 581.
WiltT., IshaniA., MacDonaldR. Serenoarepensforbenignprostatichyperplas ia (Cochrane Review) // The Cochrane Library. – 2004. – Vol. 1. – P. 24.
Montorsi F. Summary of product characteristics // Eur. Urol. – 2010. – Vol. 9. P. 491495.
http: // uroweb.otg/guideline/treatmentofnonneurogenicmaleluts/
Roehrbom C.G., et al. Serum prostatespecific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia // Urology – 1999. – Vol. 53. P. 581 589.
Boyle P., et al. Metaanalysis of randomized trials of terazosin in the treatment ofbenign prostatic hyperplasia // Urology – 2001. – Vol. 58. – P. 717–722.
Roehrbom C.G., et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4year results from the CombAT study // Eur. Urol. – 2010. – Vol. 57.P. 123131.
Giuliano F., et al. The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia // Eur. Urol. – 2013. – Vol. 63. – P. 506–616. http: // www. ncbi.nlm.nih.gov/pubmed/23018163
Morelli A., et al. Phosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously hypertensive rats // J. Sex. Med. – 2011. – Vol. 8. – P. 2746– 2760. http: // www.ncbi.nlm.nih.gov/pubmed/21812935
Vignozzi L., et al. PDE5 inhibitors blunt inflammation in human BPH: a potential mechanism of action for PDE5 inhibitors in LUTS // Prostate. – 2013. – Vol. 73. – P. 1391–1402. http: // www.ncbi.nlm.nih.gov/pubmed/23765639
Ahyai S.A., et al. Metaanalysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement // Eur.Urol. – 2010. – Vol. 58. – P. 384–397.
Madersbacher S., et al. Reoperation, myocardial infarction and mortality after transurethral and open prostatectomy: a nationwide, longterm analysis of 23,123 cases // Eur. Urol. – 2005. – Vol. 47. – P. 499–504. http: // www.ncbi. nlrn.nih.gov/pubmed/15774249
Reich O., et al. Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients // J. Urol. 2008. Vol. 180. P. 246249.
Madersbacher S, et al. Is transurethral resection of the prostate still justified // BJU Int. 1999. Vol. 83. P. 227237.
Naspro R., et al. Holmium laser enucleation of the prostate versus open prostatectomy for prostates >70 g: 24month followup // Eur.Urol. – 2006. – Vol. 50. – P. 563–568. http: // www.ncbi.nlm.nih.gov/pubmed/16713070
Skolarikos A., et al. Eighteenmonth results of a randomized prospective study comparing transurethral photoselective vaporization with transvesical open enucleation for prostatic adenomas greater than 80 cc. // J. Endourol. – 2008. – Vol. 22. P. 23332340.
Boyle P., et al. A metaanalysis of trials of transurethral needle ablation for treating symptomatic benign prostatic hyperplasia // BJU Int. – 2004 –Vol. 94. – P. 8388.
Armitage J.N., et al. Epithelializing stent for benign prostatic hyperplasia: a systematic review of the literature // J. Urol. – 2007. – Vol. 177. – P. 1619–1624

Для продолжения работы требуется Регистрация

Предыдущая страница

Следующая страница